GU Cancers 2023 | ADCs for advanced urothelial carcinoma

Daniel P. Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses antibody-drug conjugates (ADCs) in the treatment landscape of advanced urothelial carcinoma, including enfortumab vedotin and sacituzumab govitecan. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.